[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].

Date publication

septembre 2013

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno

Tous les auteurs :
Gadea E, Thivat E, Wang-Lopez Q, Viala M, Paulon R, Planchat E, Chadeyras JB, Merlin C, Coudert B, Bignon YJ, Morio B, Durando X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24045219

Résumé

Numerous studies have demonstrated that a significant change in weight during chemotherapy treatment was a factor of poor prognosis in early breast cancer women. However, the causes and mechanisms involved in this phenomenon are not fully known. This review summarizes current knowledge about the causes of energy imbalance during chemotherapy treatment and the mechanisms that have been proposed as responsible for the increased risk of relapse and death in this population. Current preventive strategies focus on physical activity programs but also on the use of metformin during and after chemotherapy.

Référence

Bull Cancer. 2013 Sep;100(9):865-70